跳至主要内容
临床试验/NCT07579910
NCT07579910尚未招募3 期

A Phase 3, Randomized, Single-blind, Parallel Group, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebroventricular Tralesinidase Alfa Treatment Compared to Standard of Care in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

Spruce Biosciences0 个研究点目标入组 14 人开始时间: 2026年12月1日最近更新:
干预措施

试验速览

阶段
3 期
状态
尚未招募
入组人数
14

研究概览

简要总结

The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
1 Year 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Has a diagnosis of MPS IIIB confirmed by deficient NAGLU enzyme activity during screening.
  • Has nonattenuated severe MPS IIIB by the Genotype and Clinical Assessment Committee.
  • Is ≥1 and ≤5 years of age with BSID-III-C raw score of <
  • Is male or female as identified at birth.

排除标准

  • Genotyped for a known MPS IIIB variant associated with an attenuated phenotype or has a sibling with a known attenuated phenotype.
  • Has another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, or hemorrhage) before study entry.
  • Has received stem cell, gene therapy, or enzyme replacement therapy for MPS IIIB.

研究组 & 干预措施

Tralesinidase alfa (TA)

Experimental

干预措施: Tralesinidase alfa (TA) (Drug)

Control

No Intervention

研究者

申办方类型
Industry
责任方
Sponsor

相似试验